Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
复制标题
DOI：
10.1016/j.bbrc.2015.06.137
复制
发表时间：
2015-12-18
影响因子：
3.1
通讯作者：
Chang EH
中科院分区：
文献类型：
--
作者：
Kim SS;Harford JB;Pirollo KF;Chang EH
多形性胶质母细胞瘤(GBM)是最具侵袭性和致命性的脑肿瘤。治疗耐药和药物透过血脑屏障(BBB)受限是导致GBM患者预后不良的主要原因。积累的证据表明，在包括GBM在内的许多人类癌症中，治疗耐药性可以归因于一小部分被称为癌症干细胞(CSCs)的癌细胞。CSC已被证明具有干细胞样的特性，使其能够逃避传统的细胞毒疗法，因此需要新的CSC导向的抗癌疗法。纳米颗粒被设计成选择性地将有效载荷输送到体内相关的靶细胞，因此将纳米颗粒用于CSC导向的抗癌治疗有相当大的兴趣。纳米药物领域的最新进展为克服CSC介导的治疗耐药提供了新的可能性，从而显著改善了对GBM的管理。在这篇综述中，我们将审查目前针对CSCs的纳米医学方法及其治疗意义。不同的纳米给药系统对基底细胞瘤中CSCs的抑制作用是本综述的重点。
Glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor. Both therapeutic resistance and restricted permeation of drugs across the blood–brain barrier (BBB) play a major role in the poor prognosis of GBM patients. Accumulated evidence suggests that in many human cancers, including GBM, therapeutic resistance can be attributed to a small fraction of cancer cells known as cancer stem cells (CSCs). CSCs have been shown to have stem cell-like properties that enable them to evade traditional cytotoxic therapies, and so new CSC-directed anti-cancer therapies are needed. Nanoparticles have been designed to selectively deliver payloads to relevant target cells in the body, and there is considerable interest in the use of nanoparticles for CSC-directed anti-cancer therapies. Recent advances in the field of nanomedicine offer new possibilities for overcoming CSC-mediated therapeutic resistance and thus significantly improving management of GBM. In this review, we will examine the current nanomedicine approaches for targeting CSCs and their therapeutic implications. The inhibitory effect of various nanoparticle-based drug delivery system towards CSCs in GBM tumors is the primary focus of this review.